| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director | Director, Former 10% Owner
6 companies
Amir Nashat is Director at RNAC and has filed Form 4s across 6 companies. From May 2015 to September 2025, the filings on record show 7 open-market purchases and 17 sales. Amir Nashat's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $19.8M at current prices.
Historically, Amir Nashat's trades have earned a below-average insider score of 49/100 across 3 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +16.9%.
The biggest single holding is RNAC (~$17.2M) as Director. Net of sales, the RNAC filings show accumulation of 1,020,042 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 25, 2017 | RNAC Cartesian Therapeutics, Inc. | Director | Sell | 79,211 | $19.13 | $1,515,663.89 | -4.7% | |
| Sep 21, 2017 | RNAC Cartesian Therapeutics, Inc. | Director | Sell | 147,187 | $19.91 | $2,930,214.88 | -8.0% | |
| Jul 6, 2016 | SYRS Syros Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | -113.7% | |
| Jun 27, 2016 | RNAC Cartesian Therapeutics, Inc. | Director, 10% Owner | Buy | 150,000 | $14.00 | $2,100,000.00 | +8.9% |